This was the stock's third consecutive day of losses.

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

In this article, we will take a look into Abbott Laboratories's (NYSE:ABT) DCF analysis, a reliable and data-driven approach ...

The stock's fall snapped a two-day winning streak.

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( LSE:0Q15) with a Overweight recommendation. What is the Fund Sentiment?

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...